X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Raleigh awards economic development incentive to Xellia Pharmaceuticals

Yuvraj_pawp by Yuvraj_pawp
8th September 2014
in Americas, News

The city will award an economic development incentive grant to Xellia Pharmaceuticals to expand its manufacturing plant on Capital Boulevard in North Raleigh.

The grant requires Xellia to create 40 permanent full-time jobs with an average annual salary of $45,000 to $70,000 in the next five years as well as maintain 90 existing jobs.

The company also must make a new property tax investment of at least $100 million.

The value of the grant was not specified; it will depend on how much Xellia pays in property taxes. The company will receive a payment worth 50 percent of the paid property taxes annually for five years.

City councilman John Odom, who represents northeast Raleigh, said the incentive ensures the area maintains high-quality jobs, but he’s skeptical of the use of incentives.

“It will be a good thing because they’re keeping the jobs up here,” he said. “But I will tell you, I’m not an incentive guy. I don’t like to do them if we don’t have to.”

The city is weighing the development of a formal economic incentive policy similar to what other Triangle governments have.

The city previously has awarded similar incentive grants to Citrix and Red Hat that were based on job creation or capital investments.

“This is in line with the others,” said James Sauls, economic development director for the city.

Red Hat, for example, must meet targets for the number of jobs in its downtown headquarters in order to receive a payment of $100,000 annually for 10 years.

Citrix was required to both meet job targets and make a $20 million investment in its downtown building. Its payment from the city also is based on a percentage of its taxes for 12 years.

Xellia specializes in the development and manufacturing of anti-infective products.

The Danish company acquired the North Raleigh plant from Fresenius Kabi, a German health care company, in July. The plant is located on Capital Boulevard just north of Thornton Road.

The plant is Xellia’s first U.S. manufacturing facility. It will expand the company’s manufacturing capacity for injectable pharmaceuticals.

“We are very pleased to be able to use this incentive to expand the site and to attract the most talented and productive employees to grow the team here further,” Xellia CEO Carl-Åke Carlsson, said in a news release.

The city council approved the incentive grant in closed session Aug. 5. Officials announced it Tuesday.

The city council’s Budget and Economic Development Committee is expected to discuss the development of an incentives policy at a Sept. 9 meeting.

Tags: America
Previous Post

Novartis data at ERS 2014 show once-daily Ultibro® Breezhaler® is superior in reducing COPD flare ups compared to Seretide®

Next Post

Cold Chain Technologies Supports the Boston Marathon® Jimmy Fund Walk Insulated packaging leader is the official sponsor of Refueling Station #6 in Wellesley, Massachusetts

Related Posts

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
Next Post

Cold Chain Technologies Supports the Boston Marathon® Jimmy Fund Walk Insulated packaging leader is the official sponsor of Refueling Station #6 in Wellesley, Massachusetts

Latest News

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In